10th INTEREST Workshop on HIV

第十届 INTEREST 艾滋病毒研讨会

基本信息

  • 批准号:
    9141914
  • 负责人:
  • 金额:
    $ 7万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-03-01 至 2017-02-28
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): The most recent UNAIDS estimates of the global burden of HIV are that 36.9 million people are currently living with HIV-1 infection and 25.8 million of them live in sub-Saharan Africa. Moreover, 70% of new infections annually are occurring in the same region of the world (UNAIDS. How AIDS Changed Everything; 2015). HIV incidence has been declining in many, but not all, African countries at a time that HIV prevalence continues to rise as more people access antiretroviral treatment. Although treatment is having important impact on slowing HIV transmission, alone it will not turn the epidemic on its head. HIV prevention remains critical to stem the tide of HIV. The UNAIDS 90-90-90 targets for 2020 aim for 90% of people living with HIV knowing their HIV status; 90% of people who know their HIV- positive status on antiretroviral treatment; and 90% of people on treatment with suppressed virus loads. The 2030 targets are 95-95-95 (UNAIDS. Fast-track: ending the AIDS epidemic by 2030; 2014). Current estimates for the African continent are that 29% of all those living with HIV have suppressed viral loads. Every step of the treatment cascade needs intensive investment: scaling up HIV testing access to diagnose those living with HIV, an immediate offer of antiretroviral treatment regardless of CD4 count, and retention in effective treatment to achieve viral suppression. Although there are many measures in place to tackle the HIV disease burden in Africa there remains much work to do in terms of training local physicians and scientists in regard to diagnosis, treatment, and management of individuals with HIV-1 infection, as well as to evidence-informed public health responses and implementation science to determine the most cost-effective use of financial and human resources. The International Workshop on HIV Treatment, Pathogenesis and Prevention Research in Resource- Limited Settings (INTEREST) Workshop was an initiative of Professors Joep M.A. Lange † (Amsterdam Institute for Global Health and Development (AIGHD), Academic Medical Center, Department of Global Health, University of Amsterdam) and Charles A.B. Boucher (Erasmus Medical Center, Rotterdam, University of Rotterdam). Together with a prominent group of international experts in the field of HIV, a focused international scientific meeting in Africa was launched in 2007. Since then, 9 successful annual meetings have been convened in Uganda, Senegal (twice), Zambia (twice), Mozambique, Tanzania, Kenya, and Zimbabwe. Known as the "African CROI" the INTEREST Workshop brings together scientists involved in HIV treatment, pathogenesis, and prevention research in Africa to share pivotal findings, promote collaboration, and transfer experiences across several fields and many continents. The organizers of the 2016 INTEREST Workshop will pursue the following objectives: 1) To showcase cutting-edge knowledge in the fields of HIV diagnosis, treatment, and prevention of HIV-1 infection. 2) To continue to foster the building of a community of African physicians and scientists who will discuss implementing local solutions for the management of patients living with HIV-1 infection and for the prevention of HIV transmission.
 描述(申请人提供):艾滋病规划署对全球艾滋病毒负担的最新估计是,目前有3690万人感染艾滋病毒-1,其中2580万人生活在撒哈拉以南非洲。此外,每年70%的新感染发生在世界同一区域(联合国艾滋病规划署。艾滋病如何改变了一切;2015年)。许多但不是所有非洲国家的艾滋病毒发病率一直在下降,而与此同时,随着更多的人获得抗逆转录病毒治疗,艾滋病毒流行率继续上升。尽管治疗对减缓艾滋病毒传播产生了重要影响,但单靠治疗并不能彻底扭转疫情。预防艾滋病毒仍然是遏制艾滋病毒浪潮的关键。联合国艾滋病规划署2020年90-90-90目标的目标是:90%的艾滋病毒携带者了解他们的艾滋病毒状况;90%的人知道他们的艾滋病毒阳性状态接受抗逆转录病毒治疗;90%的人接受抑制病毒载量的治疗。2030年的目标是95-95-95(艾滋病规划署。快车道:到2030年结束艾滋病流行;2014年)。目前对非洲大陆的估计是,所有艾滋病毒携带者中有29%的人抑制了病毒载量。治疗级联的每一步都需要大量投资:扩大艾滋病毒检测机会以诊断艾滋病毒携带者,立即提供抗逆转录病毒治疗,而不考虑CD4计数,以及保留有效治疗以实现病毒抑制。虽然已经采取了许多措施来应对非洲的艾滋病毒疾病负担,但在培训当地医生和科学家以诊断、治疗和管理艾滋病毒-1感染者方面,以及在掌握证据的公共卫生对策和执行科学以确定最具成本效益的财政和人力资源利用方面,仍有许多工作要做。资源有限环境下的艾滋病毒治疗、发病和预防研究国际讲习班是由Joep M.A.Lange†教授(阿姆斯特丹全球卫生与发展研究所、阿姆斯特丹大学全球卫生系学术医学中心)和Charles A.B.Boucher(鹿特丹伊拉斯谟医学中心,鹿特丹大学)发起的。2007年,与艾滋病毒领域的一批著名国际专家一起,在非洲发起了一次有重点的国际科学会议。此后,在乌干达、塞内加尔(两次)、赞比亚(两次)、莫桑比克、坦桑尼亚、肯尼亚和津巴布韦成功举行了9次年度会议。被称为“非洲CROI”的兴趣研讨会将参与非洲艾滋病毒治疗、发病机制和预防研究的科学家聚集在一起,分享关键发现,促进合作,并在几个领域和许多大洲转移经验。2016年兴趣研讨会的组织者将追求以下目标:1)展示艾滋病毒诊断、治疗和预防艾滋病毒-1感染领域的前沿知识。2)继续促进非洲医生和科学家社区的建设,他们将讨论实施管理艾滋病毒-1感染者和预防艾滋病毒传播的当地解决方案。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Guido Ferrari其他文献

Guido Ferrari的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Guido Ferrari', 18)}}的其他基金

SOSIP-NP/mRNA combination for novel preventive and therapeutic HIV-1 vaccine regimens
用于新型预防性和治疗性 HIV-1 疫苗方案的 SOSIP-NP/mRNA 组合
  • 批准号:
    10696131
  • 财政年份:
    2022
  • 资助金额:
    $ 7万
  • 项目类别:
SOSIP-NP/mRNA combination for novel preventive and therapeutic HIV-1 vaccine regimens
用于新型预防性和治疗性 HIV-1 疫苗方案的 SOSIP-NP/mRNA 组合
  • 批准号:
    10461584
  • 财政年份:
    2022
  • 资助金额:
    $ 7万
  • 项目类别:
Linking Antibody Cooperativity and Effector Cell Engagement
将抗体协同性和效应细胞参与联系起来
  • 批准号:
    10670258
  • 财政年份:
    2021
  • 资助金额:
    $ 7万
  • 项目类别:
Linking Antibody Cooperativity and Effector Cell Engagement
将抗体协同性和效应细胞参与联系起来
  • 批准号:
    10475288
  • 财政年份:
    2021
  • 资助金额:
    $ 7万
  • 项目类别:
Linking Antibody Cooperativity and Effector Cell Engagement
将抗体协同性和效应细胞参与联系起来
  • 批准号:
    10258151
  • 财政年份:
    2021
  • 资助金额:
    $ 7万
  • 项目类别:
Infectious Diseases in Africa: Correlates of Protection, Lessons from Vaccines and Natural Infection Studies
非洲传染病:保护的相关性、疫苗的经验教训和自然感染研究
  • 批准号:
    10012379
  • 财政年份:
    2020
  • 资助金额:
    $ 7万
  • 项目类别:
Infectious Diseases in Africa: Correlates of Protection, Lessons from Vaccines and Natural Infection Studies
非洲传染病:保护的相关性、疫苗的经验教训和自然感染研究
  • 批准号:
    10361465
  • 财政年份:
    2020
  • 资助金额:
    $ 7万
  • 项目类别:
14th International Conference on HIV Treatment, Pathogenesis, and Prevention Research (INTEREST)
第14届国际艾滋病毒治疗、发病机制和预防研究会议(INTEREST)
  • 批准号:
    10012378
  • 财政年份:
    2020
  • 资助金额:
    $ 7万
  • 项目类别:
2017 INTEREST Conference
2017年兴趣大会
  • 批准号:
    9349001
  • 财政年份:
    2017
  • 资助金额:
    $ 7万
  • 项目类别:
Antibody Cooperation mediated by Fc-gamma Receptor (FcyR)-bearing cells
由 Fc-gamma 受体 (FcyR) 携带细胞介导的抗体合作
  • 批准号:
    9140252
  • 财政年份:
    2016
  • 资助金额:
    $ 7万
  • 项目类别:

相似海外基金

Building a Systems Approach to Community Health and Health Equity for Academic Medical Centers
为学术医疗中心建立社区健康和健康公平的系统方法
  • 批准号:
    9348616
  • 财政年份:
    2016
  • 资助金额:
    $ 7万
  • 项目类别:
Building a Systems Approach to Community Health and Health Equity for Academic Medical Centers
为学术医疗中心建立社区健康和健康公平的系统方法
  • 批准号:
    9212055
  • 财政年份:
    2016
  • 资助金额:
    $ 7万
  • 项目类别:
A CONFERENCE ON THE 'CRISIS' OF ACADEMIC MEDICAL CENTERS
关于学术医疗中心“危机”的会议
  • 批准号:
    6335654
  • 财政年份:
    2000
  • 资助金额:
    $ 7万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了